Cardiff Oncology, Inc.
PLK1 INHIBITORS AND PSA LEVELS IN PROSTATE CANCER
Last updated:
Abstract:
Provided is a method comprising recommending treatment of a prostate cancer patient with a polo-like kinase-1 (PLK1) inhibitor if the patient has rising prostate specific antigen (PSA) levels. Also provided is a method comprising measuring prostate specific antigen (PSA) levels in at least two samples from a prostate cancer patient, the samples obtained from the patient at different times; and recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples increase over time, or not recommending treatment of the patient with a PLK1 inhibitor if the PSA levels in the samples do not increase over time. Additionally provided is a method comprising recommending treatment of a PLK1 inhibitor to a patient having a prostate cancer that has an altered androgen receptor that does not require ligand for activation.
Utility
25 Mar 2020
16 Jun 2022